Asthma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Asthma, a heterogeneous disease, causes variable respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough. There are millions of diagnosed prevalent cases of asthma worldwide. Although its etiology is not fully understood, certain host and environmental factors are associated with an increased risk of developing the disease.
The asthma marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and likelihood of approval (LoA) for asthma. The report also analyzes the clinical and commercial landscapes of asthma as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Leading Marketed Drugs in Asthma
The current leading marketed drugs in asthma include IL-4R and IL-5R antagonists, an IgE inhibitor, a CHRM3 antagonist, and ADRB2/glucocorticoid receptor agonists. Dupilumab, Omalizumab, and Mepolizumab are some of the drugs on the market. Regeneron Pharmaceuticals – Dupixent, F. Hoffmann-La Roche – Xolair, and Boehringer Ingelheim – Spiriva Respimat are some of the key brands involved in the production of these drugs for asthma.
Asthma Marketed Drugs Segmentation by Mechanism of Action
The majority of marketed drugs for asthma are receptor agonists and receptor antagonists. Receptor agonist, receptor antagonist, enzyme inhibitor, biological factor inhibitor, and ion channel blocker are some of the primary mechanisms of action in the marketed drugs for asthma.
Asthma Marketed Drugs Analysis, by Mechanism of Action, 2022 (%)
For more MoA insights into asthma marketed drugs, download a free report sample
Asthma Marketed Drugs Segmentation by Molecule Type
The majority of the marketed drugs for asthma are small molecules. Biologic and polymer are the other two significant molecule types in the marketed drugs for asthma.
Asthma Marketed Drugs Analysis, by Molecule Type, 2022 (%)
For more molecule type insights into the asthma marketed drugs, download a free report sample
Asthma Marketed Drugs Segmentation by Routes of Administration
More than half of the marketed drugs for asthma utilize an oral route of administration. The other four RoA in the marketed drugs for asthma are injection, inhalational, topical, and suppository.
Asthma Marketed Drugs Analysis, by Routes of Administration, 2022 (%)
For more RoA insights into the asthma marketed drugs, download a free report sample
Leading Pipeline Drugs in Asthma
In the asthma pipeline, most of the drugs currently in Phase III stage of clinical development are targeting ADRB2 or IL-4 and 5. Tezepelumab, PT027 (Albuterol + budesonide), Trelegy Ellipta, and Benralizumab are some of the primary pipeline drugs in asthma.
Asthma Pipeline Drugs Segmentation by Mechanism of Action
Mechanisms of action for asthma pipeline drugs are varied, with a large number of receptor antagonists, biological factor inhibitors, enzyme inhibitors, receptor agonists, and protein/peptide inhibitors. However, receptor antagonist has the maximum asthma pipeline drugs.
Asthma Pipeline Drugs Analysis, by Mechanisms of Action, 2022 (%)
For more MoA insights into the asthma pipeline drugs, download a free report sample
Asthma Pipeline Drugs Segmentation by Molecule Type
Currently majority of drugs in various development stages are biologics. Small molecule, and Oligonucleotide are the other two molecule types found in pipeline drugs in asthma.
Asthma Pipeline Drugs Analysis, by Molecule Types, 2022 (%)
For more molecule type insights into the asthma pipeline drugs, download a free report sample
Asthma Pipeline Drugs Segmentation by Routes of Administration
Of the pipeline drugs undergoing development for asthma with a known route of administration, injectable, inhalational, and oral therapies are all common, while only topical therapies are uncommon. Majority of the asthma pipeline drugs are injectable.
Asthma Pipeline Drugs Analysis, by Routes of Administration, 2022 (%)
For more RoA insights into the asthma pipeline drugs, download a free report sample
Top Sponsors in the Asthma Marketed and Pipeline Drugs Market
AstraZeneca has sponsored the highest number of clinical trials of all the clinical trials in asthma that were initiated over the past 10 years. GSK plc., Novartis AG, and Teva Pharmaceutical Industries Ltd are some of the other top sponsors in the clinical trials of asthma marketed and pipeline drugs market.
Asthma Marketed Drugs Market Report Overview
| Key Mechanisms of Action (Marketed Drugs) | Receptor Agonist, Receptor Antagonist, Enzyme Inhibitor, Biological Factor Inhibitor, and Ion Channel Blocker |
| Analysis Year | 2022 |
| Key Routes of Administration (Marketed Drugs) | Injections, Oral, Topical, Inhalational, And Suppository |
| Key Molecule Types (Marketed Drugs) | Small Molecule, Biologic, and Polymer |
Asthma Pipeline Drugs Market Report Overview
| Key Mechanisms of Action (Pipeline Drugs) | Receptor Antagonists, Biological Factor Inhibitors, Enzyme Inhibitors, Receptor Agonists, and Protein/Peptide Inhibitors |
| Analysis Year | 2022 |
| Key Routes of Administration (Pipeline Drugs) | Injection, Inhalational, Topical, and Oral |
| Key Molecule Types (Pipeline Drugs) | Small Molecule, Oligonucleotide, and Biologic |
| Top Sponsors | AstraZeneca, Genentech, Uriach, Faes Farma, Menarini, Sanofi, Novartis, Teva, and Celltri GSK plc., Novartis AG, and Teva Pharmaceutical Industries Ltd |
Asthma Marketed Drugs Market MoA Overview ( No of Drugs in the Pipeline, 2022)
- Receptor Agonist
- Receptor Antagonist
- Enzyme Inhibitor
- Biological Factor Inhibitor
- Ion Channel Blocker
Asthma Marketed Drugs Market RoA Overview( No of Drugs in the Pipeline, 2022)
- Injections
- Oral
- Topical
- Inhalational
- Suppository
Asthma Marketed Drugs Market Molecule Types Overview( No of Drugs in the Pipeline, 2022)
- Small Molecule
- Biologic
- Polymer
Asthma Pipeline Drugs Market MoA Overview ( No of Drugs in the Pipeline, 2022)
- Receptor Antagonists
- Biological Factor Inhibitors
- Enzyme Inhibitors
- Receptor Agonists
- Protein/Peptide Inhibitors
Asthma Pipeline Drugs Market RoA Overview ( No of Drugs in the Pipeline, 2022)
- Injection
- Inhalational
- Topical
- Oral
Asthma Pipeline Drugs Market Molecule Types Overview ( No of Drugs in the Pipeline, 2022)
- Small Molecule
- Oligonucleotide
- Biologic
Scope
GlobalData’s “Asthma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Asthma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Asthma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for asthma marketed drugs?
The key mechanisms of action for asthma marketed drugs are receptor agonist, receptor antagonist, enzyme inhibitor, biological factor inhibitor, and ion channel blocker.
-
What are the key routes of administration for asthma marketed drugs?
The key routes of administration for Asthma marketed drugs are injections, oral, topical, inhalational, and suppository.
-
What are the key molecule types for asthma marketed drugs?
The key molecule types for asthma marketed drugs are small molecule, biologic, and polymer.
-
What are the key mechanisms of action for asthma pipeline drugs?
The key mechanisms of action for asthma pipeline drugs are receptor antagonists, biological factor inhibitors, enzyme inhibitors, receptor agonists, and protein/peptide inhibitors.
-
What are the key routes of administration for asthma pipeline drugs?
The key routes of administration for asthma pipeline drugs are injection, inhalational, topical, and oral.
-
What are the key molecule types for asthma pipeline drugs?
The key molecule types for asthma pipeline drugs are small molecule, oligonucleotide, and biologic.
-
Who are the top sponsors in the asthma marketed and pipeline drugs market?
Some of the top sponsors in the asthma marketed and pipeline drugs market are AstraZeneca, Genentech, Uriach, Faes Farma, Menarini, Sanofi, Novartis, Teva, and Celltri GSK plc., Novartis AG, and Teva Pharmaceutical Industries Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Asthma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Respiratory reports